Australia's Argent BioPharma rises on partnership with ECCPharm
05/03/2025 01:07
** Shares of Argent BioPharma RGT.AX rise 24.1% to A$0.180 ** Drug discovery firm says it has entered a strategic manufacturing partnership with ECCPharm ** Under the deal, ECCPharm will manufacture and batch release co’s cannabinoid therapies ** Trade vols at 3x the 30-day avg of 33,207 shares ** RGT up 5.9% YTD (Reporting by Adwitiya Srivastava in Bengaluru) ((Adwitiya.Srivastava@thomsonreuters.com))
Recent news on Argent BioPharma
See all newsBrief: Argent Biopharma Enters Long Term Aquiol Licensing And Supply Agreement
Brief: Argent Biopharma Secures A$11M Financing Facility To Complete Strategic Acquisition
Brief: Argent Is Growing Through M&A Projected Merged Company Value Of $100M In Ac8 Asset Acquisition
Australia's Argent BioPharma set for best day in a year on AusCann deal
Brief: Argent Biopharma To Acquire Core Operating Assets And IP Portfolio Of Auscann Group